91 related articles for article (PubMed ID: 15623805)
21. [RET and GFRA1 germline polymorphisms in medullary thyroid cancer patients].
Severskaia NV; Saenko VA; Il'in AA; Chebotareva IV; Rumiantsev PO; Isaev PA; Medvedev VS; Iasmita S
Mol Biol (Mosk); 2006; 40(3):425-35. PubMed ID: 16813162
[TBL] [Abstract][Full Text] [Related]
22. Sporadic medullary thyroid carcinoma associated with toxic multinodular goitre.
Small PK; Smith D
J R Coll Surg Edinb; 1997 Jun; 42(3):199-200. PubMed ID: 9195818
[TBL] [Abstract][Full Text] [Related]
23. Early malignant progression of hereditary medullary thyroid cancer.
Machens A; Niccoli-Sire P; Hoegel J; Frank-Raue K; van Vroonhoven TJ; Roeher HD; Wahl RA; Lamesch P; Raue F; Conte-Devolx B; Dralle H;
N Engl J Med; 2003 Oct; 349(16):1517-25. PubMed ID: 14561794
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and management of medullary thyroid carcinoma.
Massoll N; Mazzaferri EL
Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
[TBL] [Abstract][Full Text] [Related]
25. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
[TBL] [Abstract][Full Text] [Related]
26. Germline succinate dehydrogenase subunit D mutation segregating with familial non-RET C cell hyperplasia.
Lima J; Teixeira-Gomes J; Soares P; Máximo V; Honavar M; Williams D; Sobrinho-Simões M
J Clin Endocrinol Metab; 2003 Oct; 88(10):4932-7. PubMed ID: 14557476
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.
Elisei R; Cosci B; Romei C; Agate L; Piampiani P; Miccoli P; Berti P; Basolo F; Ugolini C; Ciampi R; Nikiforov Y; Pinchera A
J Clin Endocrinol Metab; 2004 Nov; 89(11):5823-7. PubMed ID: 15531548
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
[TBL] [Abstract][Full Text] [Related]
29. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
30. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
31. Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.
Sakorafas GH; Nasikas D; Thanos D; Gantzoulas S
Oncol Res Treat; 2015; 38(5):249-52. PubMed ID: 25966772
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.
Allen SM; Bodenner D; Suen JY; Richter GT
Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888
[TBL] [Abstract][Full Text] [Related]
33. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer.
Machens A; Frank-Raue K; Lorenz K; Rondot S; Raue F; Dralle H
Clin Endocrinol (Oxf); 2012 May; 76(5):691-7. PubMed ID: 22111543
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
36. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
[TBL] [Abstract][Full Text] [Related]
37. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
38. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
[TBL] [Abstract][Full Text] [Related]
39. [The treatment of medullary thyroid cancer].
Fujita T; Fujimori M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
[TBL] [Abstract][Full Text] [Related]
40. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
